NCT02526875

Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Detailed description

A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Telminuvo®Tab. 40/2.5mg	per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

Timeline

• Start date: 2015-04-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2015-08-18
• Last updated: 2017-08-22

Locations

10 sites across 1 country: South Korea